US 11,719,711 B2
Compositions and methods for detecting and/or treating inflammation
Sylvie Breton, Belmont, NH (US); Dennis Brown, Natick, MA (US); Anie Azroyan, Boulogne-Billancourt (FR); Virna F. Cortez-Retamozo, Cambridge, MA (US); and Mikael Pittet, Charlestown, MA (US)
Assigned to THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
Filed by THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
Filed on Jan. 26, 2021, as Appl. No. 17/158,079.
Application 17/158,079 is a continuation of application No. 16/375,332, filed on Apr. 4, 2019, granted, now 10,935,556.
Application 16/375,332 is a continuation of application No. 15/860,937, filed on Jan. 3, 2018, abandoned.
Application 15/860,937 is a continuation of application No. 15/035,033, granted, now 9,891,236, issued on Feb. 13, 2018, previously published as PCT/US2014/064525, filed on Nov. 7, 2014.
Claims priority of provisional application 61/931,146, filed on Jan. 24, 2014.
Claims priority of provisional application 61/931,184, filed on Jan. 24, 2014.
Claims priority of provisional application 61/962,476, filed on Nov. 7, 2013.
Prior Publication US 2021/0231688 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/74 (2006.01); G01N 33/53 (2006.01); G01N 33/566 (2006.01); G01N 33/66 (2006.01); A61K 31/451 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC G01N 33/74 (2013.01) [A61K 31/451 (2013.01); C07K 16/28 (2013.01); G01N 33/5308 (2013.01); G01N 33/566 (2013.01); G01N 33/66 (2013.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/76 (2013.01); G01N 2333/726 (2013.01); G01N 2800/347 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7095 (2013.01)] 17 Claims
 
1. A method of treating a subject determined to have a level of UDP-glucose above a reference level as indicative of renal inflammation, the method comprising administering a treatment appropriate for treating renal inflammation in said subject, wherein the treatment appropriate for treating renal inflammation comprises a P2Y14 inhibitor.